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ABSTRACT
Objective: The present study describes the use of in situ gel in periodontal drug delivery systems which contain gellan gum (0.4-0.6% w/v), pluronic 
F127 (14, 15, and 16% w/v), and drug ciprofloxacin HCl (0.1% w/v). Number of peoples around the world suffered from dental problem and ultimate 
fear is tooth loss hence in situ gelling system was designed for the treatment of periodontal diseases. The therapeutic efficacy of drug can be greatly 
improved by prolonging its contact time.
Methods: Formulations were developed by simple solution method. Each formulation was characterized in terms of in gelling strength, viscosity, 
rheology, content uniformity, in vitro drug release, and syringeability.
Results: In vitro gelation time and the nature of the gel formed in simulated saliva for prepared formulations showed polymeric concentration 
dependency. Drug release data from all formulations were fitted to different kinetic models, and the Korsmeyer-Peppas model was the best fit model. 
Drug release was significantly decreased as the concentration of each polymer component was increased. Increasing the concentration of each 
polymeric component significantly increased viscosity, syringeability, and time for 50%, 70%, and 90% drug release. In conclusion, the formulations 
described offer a wide range of physical and drug release characteristics. The formulation containing 0.6% w/v of gellan gum and 14% w/v of pluronic 
F127 exhibited superior physical characteristics. The formulation stored at 4°C before application, which is syringeable through 21 gauge needle.
Conclusion: This formulation was made to inject directly into periodontal pocket where it immediately converts into gel form at body temperature.
Keywords: Periodontitis, Poloxamer 407, Gelation temperature, Syringeability, Subgingival dental plaque.
INTRODUCTION
Periodontal diseases are renowned as the main community problem 
worldwide. Dental diseases are surrounded by the most widespread 
chronic disorders affecting the human health. Periodontitis is an 
inflammation of the gingival and the deeper periodontal tissues. 
Periodontitis is pave the way and accompanied by gingivitis. However, 
gingivitis may persist without progressing to periodontitis foremost 
to the loss of supporting structure of teeth and the deeper tissues 
which affect the supportive structures of the teeth [1]. The periodontal 
pocket provides diverse surroundings for the immigration of gram-
negative anaerobes such as Porphyromonas gingivalis, Bacteroides spp., 
Capnocytophaga spp., and Actinobacillus actionomycetemcomitns The 
bacteria build up in the periodontal pocket that widen between the 
roots of affected teeth and soft tissues [2]. If the disease is allowed to 
progress, increased tooth mobility and probably results in loss of tooth 
loss. As a result of pathologic changes, the gingival attachment to the 
tooth may become displaced, and a space forms between this detached 
gingiva and the tooth is called a pocket [3].
The ultimate result of progressive pocket formation leads to bone 
loss and tooth mobility. The systemic administration has been useful 
in treating periodontal pockets, but repetitive and extensive use of 
systemic drugs is burdened with potential danger including resistant 
strains and superimposed infections. To overcome the aforesaid 
drawbacks of conventional preparations, we tried to fabricate and 
to evaluate suitable drug delivery system with the aim of improving 
patient compliance, therapeutic efficacy, reduced dosing frequency and 
site specific drug action with adhesion and biodegradable polymeric 
systems. Local administration provides a useful answer to these 
problems. The antibacterial spectrum of Ciprofloxacin HCl includes 
bacteria such as the Peptostreptococcus species, Clostridium difficile, the 
Clostridium species, Bacteroids species, Bacteroids fragilis, Provotella 
species, Porphyromonas species, Fusobacterium species, Actinomycetes, 
Propionibacterium species, and the Eubacterium species. The drug is 
found to be most effectual against various Protozoa, namely, Trichomonas 
vaginalis, Entamoeba histolytica, and Giardiasis intestinalis. Bioadhesion 
may be defined as the condition in which two substances, at least one 
of them is from a biological source, are held together for extended 
periods of time by interfacial forces. For drug delivery purposes, the 
word bioadhesion involves the adhesion of a drug delivery system to a 
specific biological membrane. The biological surface can be epithelial 
tissue or the mucous coat on the surface of tissue. If hold attachment is 
to a mucous coat, the phenomenon is referred to as mucoadhesion [4].
In recent times, most of the scientists, students, researchers have 
paying attention on placing an API or API loaded formulations at a 
specific site in the body using bioadhesive water soluble polymers 
to control the delivery of biologically active agents systemically 
or locally [5] Biodegradable excipients have been used in drug 
delivery system. Because of their biodegradability, there is no any 
kind of requirement to take away the formulations exhausted with 
delivery devices. The exploitation of bioabsorbable delivery strategy 
represents a main step forward in the management of periodontal 
diseases. There remainder a call for in the art for the delivery device, 
which can be controlled more quickly and easily positioned in a 
periodontal pocket for the release of beneficial agent for a longer 
duration to treat the disease condition. The primary benefit of in situ 
gels is that they can be easily administer with precise & reproducible 
dose compared with that of performed gels and have an advantage 
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that they can be without difficulty instilled in liquid form, and are 
capable of make longer the residence time [6].
MATERIALS AND METHODS
Materials
Ciprofloxacin HCl was obtained as a gift sample from Alembic 
Pharmaceuticals Pvt. Ltd., Mumbai, India. Pluronic F-127 and Gellan 
gum (Kelcogel®) was from Sigma-aldrich, Pvt. Ltd. (Germany), and 
purchased from Sudarshan Scientific Labortories, Nashik (MS) and 
Dialysis Membrane MWCO 12000 Da. Purchased from Hi Media 
(Mumbai, India) Deionised water was used as the aqueous component. 
Other all the chemicals used was of analytical grade.
Microbiological material
A bacterial and fungal strain was procured from microbial test culture 
collection (MTCC) Escherichia coli (MTCC 614), and Staphylococcus 
aureus (MTCC 1430). Nutrient agar and Potato dextrose agar was 
purchased from HiMedia Mumbai.
Preformulation studies
Tests were carried out on the sample of the drug to establish its 
identity and purity as per specification reported in Indian/British 
Pharmacopoeia. The parameters studied include appearance, solubility 
in different solvents, melting point, infrared spectra, determination of 
λmax in phosphate buffer pH 7.4 and distilled water [7].
Ultraviolet (UV) spectra were measured on (UV 1700, Shimadzu) 
double beam spectrophotometer to construct the standard curve for 
Ciprofloxacin HCl at 271 nm. The melting point of Ciprofloxacin HCl 
was obtained by differential scanning calorimetry (DSC) study (Fig. 2). 
Infrared spectra of the physical mixture were analyzed by Fourier 
transform infrared (FTIR) (Shimadzu) (Fig. 1). DSC of pure drug and 
polymers were conducted using Differential Scanning Calorimetry 
(DSC 822c, Mettler Toledo) at heating rate of 10°C/minutes over a 
temperature range of 35-300°C under an inert atmosphere flushed with 
nitrogen at a rate of 30 ml/minutes. Drug-polymer interaction studies 
were performed by FTIR spectroscopy by KBr pellet method.
Preparation of gel formulation
Dry Gellan gum powder was dispersed in 90 ml of distilled water 
maintained at 95°C. The dispersion was stirred at 95°C for 20 minutes 
using a magnetic stirrer to facilitate hydration of gellan gum. The 
required amounts of preservatives (methylparaben and propylparaben) 
and disodium edetate were added to the gellan gum solution with 
continuous stirring at 95°C. The solution was allowed to cool to room 
temperature. The required amount of Ciprofloxacin HCl was added 
to the gellan gum solution with continuous stirring until the entire 
Fig. 1: Incompatibility study by Fourier transform infrared spectroscopy
Fig. 2: Differential scanning calorimetry thermogram of pure drug
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drug was dissolved. The required amount of Pluronic F127 was added 
with continuous mild stirring for 5 min. The formulations containing 
partially dissolved Pluronic F127 were stored in the refrigerator 
until the entire polymer was completely dissolved (~48 hrs). The 
formulations were prepared using different concentrations of gellan 
gum varying from 0.4% to 0.6% w/v and Pluronic F127 varying from 
14% to 16%w/v. The final volume was adjusted to 100 ml with distilled, 
deionized water [8]. The composition of in situ gel is shown in Table 1.
Evaluation parameter
Physical properties
The appearances of formulations were observed by visual observation. 
The observed appearances of the prepared systems were tested on 
color, clarity.
Drug content
Formulations containing 1 mg drug were taken in 10 ml volumetric 
flask dissolve in distilled water then made up the volume to 10 ml 
with distilled water then filtered. Absorbance values were measured 
with suitable dilutions of 2-14 µg/ml at λmax 271 nm by UV 
spectrophotometer. Concentrations of the drug were calculated from 
the standard calibration curve prepared in methanol as stated by to get 
the drug content [9].
pH of formulation
An acidic or alkaline formulation is bound to cause irritation on mucosal 
membrane, and hence this parameter assumes significance while 
developing a mucoadhesive formulation. 1 ml of distilled water was added 
on to the formulation; pH was measured by allowing the electrode of a pH 
meter to come in contact with the formulation for 1 minute to equilibrate. 
A digital glass electrode pH meter was used for this purpose. pH was noted 
by bringing the electrode pH was noted by bringing the electrode near the 
formulations and allowing to equilibrate for 1 minute [8].
Gelation study
Gelation studies were carried out using temperature change and by the 
introduction of ions. In these studies the gelling capacity (speed and 
extent of gelation) for all formulations were determined. After easy 
instillation into periodontal pocket, the liquid polymeric solutions 
should undergo rapid sol to gel transition by means of thermosensitivity 
and ion-induced gelation. Thus, the in situ formed gel should preserve 
its integrity without dissolving or eroding so as to localize the drug at 
absorption site for the extended duration [10].
In vitro gelling capacity
The in vitro gelling capacity measurement of the formulations in the 
presence of cations (which are present in simulated saliva) was carried 
out by two methods.
In vitro gelling capacity by visual method
To evaluate the formulations for its in vitro gelling capacity by the 
visual method, colored solution of gel (batches F1-F9) were prepared. 
The in vitro gelling capacity of prepared formulations was measured by 
placing 2 ml of simulated saliva in a 15 ml borosilicate glass test tube 
and maintained at 37±1°C temperature. 1 ml of colored formulation 
solution was added with the help of a 1 ml pipette. The formulation 
was transferred in such a way that places the pipette at the surface of 
the fluid in the test tube and formulation was slowly released from the 
pipette. As the gel formulation comes into contact with simulated saliva, 
it was immediately converted into a stiff gel-like structure. The gelling 
capacity of gel was evaluated on the basis of stiffness and time period 
for which the formed gel remains as such. Color was added to give a 
visual appearance to the formed gel. The in vitro gelling capacity was 
graded in three categories on the basis of gelation time and time period 
for which the formed gel remains [11].
In vitro gelling capacity by viscosity measurement
Viscosities of formulations before and after gelation were measured 
using Brookfield DV-E viscometer using Spindle number-3 at 100 rpm 
shear rate. In case of Pluronic F127 based systems, the viscosity was 
recorded at increasing temperature in the range of 20-30°C and graphs 
were plotted. From which an approximate gelation temperature was 
determined as indicated by sudden rise of viscosity [11];
• (+), gels after few minutes, dispersed rapidly;
• (++), gelation immediate, remains for few hours;
• (+++), gelation immediate, remains for an extended period.
Viscosity measurements viscosities of formulations before and after 
gelation were measured by using Brookfield DV-E viscometer using 
Spindle number 4 at 100 rpm shear rate. In case of Pluronic F127 and 
gellan gum-based systems the viscosity was recorded at increasing 
temperature in the range of 20-30°C, and the introduction of ions and 
graphs were plotted. From which an approximate gelation temperature 
was determined as indicated by the sudden rise of viscosity [12].
Syringeability study
All the developed formulations were tested syringeability through 
21-gauge needle [13].
Fig. 3: Viscosity profile of sol at 25’c and gel 37’
Fig. 4: In vitro drug release of in situ gel formulations
Fig. 5: Higuchi plot of formulation F7
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In vitro drug release kinetics
In vitro drug release study was performed using a Franz diffusion cell 
consisting of two glass compartments, a sampling port, a teflon coated 
magnetic stirrer bead, and a synthetic cellulose membrane (0.45 µm). 
Simulated saliva having pH 7.4 was used as a dissolution medium. The 
diffusion cell was water jacketed, and temperature was maintained at 
37±1°C by continuous circulation of water, in a water bath with a mini-
submersible pump. The Franz diffusion cell was placed on a magnetic 
stirrer, and the stirring rate was maintained at ~250-300 rpm. After 
equilibration of the dissolution medium at 37±1°C, 1 ml of sample was 
placed on synthetic cellulose membrane in the donor compartment 
of the cell with the help of a syringe. Before placing the formulation 
to the membrane ~2 ml of dissolution medium was placed on the 
membrane, and the whole assembly was allowed to equilibrate at 
37±1°C. At predetermined time intervals, 1 ml samples of the receptor 
fluid were taken for 240 minutes. The medium was replaced after 
each sampling. Ciprofloxacin HCl concentration in each sample was 
determined by diluting 1 ml of sample up to 100 ml and analyzed 
spectrophotometrically at 271 nm using UV-visible spectrophotometer 
by Shimadzu, Japan [14].
The release data obtained was fitted into Korsmeyer-Peppas and 
Higuchi diffusion model to find the mechanism of release from the 
formulations [15].
The diffusion study reveals the pattern of drug release from the 
formulated gel. The in-vitro release data of formulation F7 was treated 
with Higuchi’s diffusion equation.
(Q = kt1/2) (1)
The graph between percentage cumulative drug release and square root 
of time showed almost linear relationship after the initial period. The 
drug transport mechanism of the same formulations was determined 
using the Korsmeyer-Peppas exponential equation.
[(Mt/M) = ktn] (2)
From the plot of log (Mt/M); fraction of drug released at time “t” versus 
log of time. The kinetic parameters “n” and “k” were calculated from the 
equation. The calculated slop from the equation predicts the behavior 
of the drug release [16].
Stability study
Stability study was carried out on optimized formulation F7 at 30±2°C 
temperature and 60±5% RH for 90 days. At a periodic interval, sample 
was withdrawn and was observed for clarity, pH, viscosity, syringeability, 
and drug content at the interval of 30 days. All the measurements were 
performed after allowing the samples to equilibrate at 25°C [17].
Anti-microbial activity
The antimicrobial efficiency and prolonged effect of selected controlled 
release ciprofloxacin HCl in situ gel were determined on S. aureus and 
Table 1: Composition of in situ gel
S. No. Formulation code Formulation composition (w/v) %
Ciprofloxacin HCl (w/v) % Gellan gum Pluronic F-127 Disodium edeatate Distilled water (ml)
1 F1 0.1 0.4 14 0.1 q.s.
2 F2 0.1 0.4 15 0.1 q.s.
3 F3 0.1 0.4 16 0.1 q.s.
4 F4 0.1 0.5 14 0.1 q.s.
5 F5 0.1 0.5 15 0.1 q.s.
6 F6 0.1 0.5 16 0.1 q.s.
7 F7 0.1 0.6 14 0.1 q.s.
8 F8 0.1 0.6 15 0.1 q.s.
9 F9 0.1 0.6 16 0.1 q.s.
All formulations were added with 0.18% w/v of methylparaben, 0.02% w/v of propylparaben
Table 2: Parameters for dependence of mechanism on n value
>0.5 Quasi fickian
0.5 Fickian diffusion
0.5<n < 1.0 Anomalous (Non-fickian) transport
1.0 Non fickian case II transport
n>1.0 Non fickian super case II
Table 3: Results of gelation study










-: No gelation, +: Weak gelation, dissolves rapidly, ++: Immediate gelation 
remains for few hrs (less stiff gel), +++: Immediate gelation remains for 
extended period (Stiff gel), ++++: Very stiff gel
Table 4: Viscosity of sol at 25°C and gel at 37°C
S. No Viscosity (cps) (mean±SD)
At room temp, i.e., 
25° C±0.5 in water










Table 5: In vitro drug release study
S. No Formulation 
code
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E. coli strains as a function of time. The inhibitory effect of formulation 
on the studied microorganisms was evaluated using agar well diffusion 
test. Wells were punched into the nutrient agar previously seeded with 
test organisms and wells were filled with 100 µl of the samples. After 
allowing diffusion of solution for two-hour the plates were incubated 
for 24 hrs at 37°C, and the diameters of inhibition zones were measured. 
The inhibitory effect of optimized gel formulation was compared with 
standard [18].
RESULTS AND DISCUSSION
IR spectra of drug and free polymers showed no matching peaks with 
the drug spectra. The characteristic peaks of the drug (1400-1000, 
3400-3000, 3050-3000, 1718, 1400-1200 cm−1) were also appeared in 
the spectra of all the drug- polymer combination which is evidence of 
no interaction between any of the polymer with drug or between both 
the polymers (Fg. 1).
Ciprofloxacin HCl was confirmed by DSC which exhibits a sharp 
melting endothermic peak at temperature of 314 -318°C as shown in 
Fig. 2. Reported peak temperature was 312-314°C. DSC thermogram 
showed that there was no any major difference in peak endothermic 
temperature when compared with pure drug’s thermogram.
The prepared in situ gels containing ciprofloxacin HCl was found to 
be transparent, clear and the color of formulation was found to be 
yellowish.
The drug content of the formulations was found to be in the range of 
98.2% and 99.54%. Hence, on that basis, we can say that the drug was 
uniformly distributed throughout the formulation.
The pH of all the formulations prepared using a combination of gellan 
gum and lutrol F127, and a combination of both was observed in the 
range of 6.9-7.4. Therefore, there was no need for pH adjustment by any 
external alkalinizing agent.
All the formulations were tested as per that of the visual inspection 
and the time required to change the phase from sol-gel in physiological 
conditions (Table 3).
The viscosity of the selected formulations was measured at two 
different conditions.
Formulations were prepared in distilled water
Viscosity was measured at formulation pH and 25°C temperature.
Formulations were prepared in simulated saliva
Viscosity was measured at pH 7.4 and 37°C temperature (physiological 
condition).
The apparent viscosity values were measured for liquid formulations 
and gel using Brookfield viscometer DV-E with spindle no. 3 at 100 rpm. 
The selected formulations were poured into the sample adaptor of 
the viscometer and viscosity was measured. The measurements were 
carried out using spindle no. 3 at the speed of 50-100 rpm in the 
sample and the viscosity was measured at 10 min after the rotation of 
the spindle. The viscosity measurements were made in triplicate using 
fresh samples each time (Table 4).
The marked increase in viscosity of the liquid (sol) formulations was 
increased from 1674.0 to 1797.0 cps as the concentration of Pluronic 
F 127 increased from 14 to 16% and gellan gum was 0.4 to 0.6% w/v. 
It was also seen that the viscosity of the gel formulation was increased 
from 33317 to 39189 cps as the temperature and ions come in contact 
of the formulation (Fig. 3). Thus, increase in the concentration of the 
polymers leads to the increase in the viscosity of the formulation.
All the formulation was found to be easily injectable through 21 gauge 
needle at 25°C temperature. This facilitate to injection of sol directly 
into the periodontal pocket.
The in vitro drug release profiles of all the prepared formulations were 
executed using vertical Franz’s diffusion cell (capacity: 14 ml) with 
synthetic dialysis membrane. Phosphate buffer pH 7.4 was used as a 
diffusion media. Initially, an incomplete gel formation result in the 
quick release of drug, but the release rate was found to be significantly 
decreased with time due to complete gel formation. With increase in the 
concentration of pluronic F-127 and gellan gum the release rates were 
found to decrease gradually. The release profiles exhibited an inflection 
point, which indicated the gel formation in the donor compartment 
of the diffusion cell. During gel formation, a portion of drug might be 
loaded into the gel matrix, thus, the cross-linking of polymer reduces 
the drug release rate. The presence of aqueous phase exhibited the 
formation of porous prehydrated matrix. This results in the initial rapid 
release of drug from the prepared formulations. The results showed 
that the formed gels had the ability to extend the release of drug for the 
duration of about 240 minutes (Table 5).
In vitro release study indicated that the release of drug varied according 
to the type and concentration of polymers. The results further showed 
that the amount of the drug released in the first hour decreased with the 
increase in both the polymer concentration and this pattern continued 
till the entire duration of the study as shown in Figure 4.
To determine the release of a drug accurately from in situ gelling 
formulations, the cumulative percentage drug release data of 
formulation batch F7 was subjected to the Higuchi’s diffusion equation 
(Q = kt1/2). Following the initial time period, the graph between 
percentage cumulative drug release and square root of time exhibited 
almost linear correlation. Owing to incomplete gel formation, it was not 
possible to correlate the drug release in the early phase of drug release 
study. As the gel is formed completely, the release profiles were found 
to be linear with the square root of time and followed the Higuchi’s 
equation (Fig. 5). The slope of the plot of F7 formulations was observed 
to be 2.010, indicating the anomalous transport mechanism (Table 2). 
Based on the gelation properties, physicochemical characteristics and 
in vitro drug diffusion profiles, the formulation batch F7 was selected as 
an optimized in situ gelling formulation, and it was subjected for further 
studies.
The antibacterial study was carried out against the E. coli and S. aureus 
which is gram negative bacteria using test and standard formulation. 
The test sample and standard sample shows 52mm and 45 mm 
for E. coli and 78 mm and 58 mm for S. aureus zone of inhibition, 
respectively. The inhibition rates to E. coli and S. aureus of the test 
and standard material after 24 hrs is shown in Fig. 6a and b. These 
results can be attributed to the ability of ciprofloxacin hydrochloride 
in situ gel which inhibits the DNA gyrase of bacteria. This indicates 
Table 6: Stability study data of F7 formulation
S. No Parameters Storage period (days) at 30±2°C temperature and 60±5% RH
0 30 60 90
1 Appearance Clear white Clear white Clear white Clear white
2 Drug content (%) 99.52±0.04 99.60±1.41 98.74±1.27 98.92±1.34
3 Gelation study +++ +++ ++ ++
4 In vitro drug release (%) 99.59 98.41 98.24 98.08
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that the test sample have better antibacterial activity as compared to 
a standard sample.
The stability study carried out on optimized formulation F7 at 
30±2°C temperature and 60±5% RH for 90 days. The formulation 
was showing good stability with no significant change in gelation and 
physicochemical properties and in vitro drug release profile as shown 
in Table 6. At a periodic interval sample were withdrawn and were 
observed for clarity, pH, viscosity, syringeability, and drug content at 
the interval of 30 days. All the measurements were performed after 
allowing the samples to equilibrate at 25°C.
CONCLUSION
In the present work formulations containing drug ciprofloxacin HCl 
by the use of gellan gum and Pluronic F-127, in situ gelling system was 
developed for the management of periodontal diseases. The developed 
formulation exhibited satisfactory findings from the aforesaid study. 
In vitro drug release studies showed a polymer concentration-
dependent decrease in drug release. As the polymer concentration 
decreases the release rate profile increases. All the formulations 
developed by using different concentrations of gellan gum and Pluronic 
F-127 varying from 0.4 to 0.6% and 14-16% extend the release of drug 
up to a 3-4 hrs. The desired drug release and viscosity profile was 
executed by F7 containing 0.6% w/v gellan gum and 14% w/v pluronic 
F127 was considered as optimum formulation on the basis of optimum 
viscosity, in vitro drug release profile at initial period, and then its 
capacity to extend the release rate up to 4 hrs.
Thus, developed in situ gelling systems improves the patient’s 
compliances, reduces the dose of the drug and related side effects, 
hence, the bioavailability of the drug increases. The formulated in situ 
gelling system shows a promising approach towards the treatment 
so in future such kind of drug delivery will be definitely helpful to 
periodontal patients.
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